Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 348

1.

Impact of natural Neuromedin-B receptor variants on iron metabolism.

Rametta R, Dongiovanni P, Baselli GA, Pelusi S, Meroni M, Fracanzani AL, Busti F, Castagna A, Scarlini S, Corradini E, Pietrangelo A, Girelli D, Fargion S, Valenti L.

Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25679. [Epub ahead of print]

PMID:
31724192
2.

Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.

Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G.

World J Gastroenterol. 2019 Oct 28;25(40):6094-6106. doi: 10.3748/wjg.v25.i40.6094.

3.

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance.

Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P.

Nutrients. 2019 Oct 29;11(11). pii: E2597. doi: 10.3390/nu11112597.

4.

β-Klotho gene variation is associated with liver damage in children with NAFLD.

Dongiovanni P, Crudele A, Panera N, Romito I, Meroni M, De Stefanis C, Palma A, Comparcola D, Fracanzani AL, Miele L, Valenti L, Nobili V, Alisi A.

J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30613-0. doi: 10.1016/j.jhep.2019.10.011. [Epub ahead of print]

5.

Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.

Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley TW, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber RE, Canbay A, Link A, Valenti L, Grove JI, Aithal GP, Marquardt JU, Fateen W, Zopf S, Dufour JF, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan MY.

Hepatology. 2019 Oct 19. doi: 10.1002/hep.30996. [Epub ahead of print]

PMID:
31630428
6.

Dietary supplements, drugs and doping in the sport society.

Savino G, Valenti L, D'Alisera R, Pinelli M, Persi Y, Trenti T; WDPP, Working Group Doping Prevention Project.

Ann Ig. 2019 Nov-Dec;31(6):548-555. doi: 10.7416/ai.2019.2315.

7.

Liver International: Anticipating the future of hepatology worldwide.

Valenti L, Aghemo A, Forner A.

Liver Int. 2019 Oct;39(10):1796-1797. doi: 10.1111/liv.14240. No abstract available.

PMID:
31553529
8.

A Patient with Graves' Disease Scheduled for Thyroidectomy with High Risk for Thyroid Storm Caused by Severe Medication Nonadherence: Anaesthetic and Surgical Considerations.

Reber A, Valenti L, Müller S.

Case Rep Anesthesiol. 2019 Jul 22;2019:4781902. doi: 10.1155/2019/4781902. eCollection 2019.

9.

A simple surface biofunctionalization strategy to inhibit the biofilm formation by Staphylococcus aureus on solid substrates.

Martín ML, Dassie SA, Valenti LE, Giacomelli CE.

Colloids Surf B Biointerfaces. 2019 Nov 1;183:110432. doi: 10.1016/j.colsurfb.2019.110432. Epub 2019 Aug 7.

PMID:
31421403
10.

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.

Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, Lindén D, Whatling C, Janefeldt A, Kozyra M, Ingelman-Sundberg M, Valenti L, Andersson TB, Romeo S.

Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.

11.

Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial.

Sitzia C, Meregalli M, Belicchi M, Farini A, Arosio M, Bestetti D, Villa C, Valenti L, Brambilla P, Torrente Y.

Front Neurol. 2019 Jul 23;10:755. doi: 10.3389/fneur.2019.00755. eCollection 2019.

12.

Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease.

Taliento AE, Dallio M, Federico A, Prati D, Valenti L.

Int J Environ Res Public Health. 2019 Aug 1;16(15). pii: E2755. doi: 10.3390/ijerph16152755. Review.

13.

Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges.

Valenti L, Pelusi S, Baselli G.

J Hepatol. 2019 Oct;71(4):849-850. doi: 10.1016/j.jhep.2019.06.008. Epub 2019 Jul 27. No abstract available.

PMID:
31362836
14.

NAFLD in children: new genes, new diagnostic modalities and new drugs.

Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N.

Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):517-530. doi: 10.1038/s41575-019-0169-z. Epub 2019 Jul 5. Review.

PMID:
31278377
15.

Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.

Zusi C, Mantovani A, Olivieri F, Morandi A, Corradi M, Miraglia Del Giudice E, Dauriz M, Valenti L, Byrne CD, Targher G, Maffeis C.

Dig Liver Dis. 2019 Nov;51(11):1586-1592. doi: 10.1016/j.dld.2019.05.029. Epub 2019 Jun 27.

PMID:
31255630
16.

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.

Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.

Liver Int. 2019 Sep;39(9):1742-1754. doi: 10.1111/liv.14167. Epub 2019 Jun 26.

17.

Building mass to prevent non-alcoholic fatty liver disease?

Pelusi S, Valenti L.

Hepatobiliary Surg Nutr. 2019 Apr;8(2):173-176. doi: 10.21037/hbsn.2018.12.07. No abstract available.

18.

Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.

Mantovani A, Turino T, Altomari A, Lonardo A, Zoppini G, Valenti L, Tilg H, Byrne CD, Targher G.

Metabolism. 2019 Jul;96:56-65. doi: 10.1016/j.metabol.2019.04.012. Epub 2019 Apr 29.

PMID:
31047909
19.

Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review.

Besutti G, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P.

Liver Int. 2019 Aug;39(8):1521-1534. doi: 10.1111/liv.14118. Epub 2019 May 8.

PMID:
30972903
20.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
21.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

22.

Post-transplant metabolic syndrome in children: Know better to cure better.

Nobili V, Pietrobattista A, Valenti L, Spada M.

Pediatr Transplant. 2019 May;23(3):e13367. doi: 10.1111/petr.13367. Epub 2019 Feb 21. No abstract available.

PMID:
30793446
23.

Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.

Lindén D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andréasson AC, Sasidharan K, Madeyski-Bengtson K, Zurek M, Mancina RM, Lindblom A, Bjursell M, Böttcher G, Ståhlman M, Bohlooly-Y M, Haynes WG, Carlsson B, Graham M, Lee R, Murray S, Valenti L, Bhanot S, Åkerblad P, Romeo S.

Mol Metab. 2019 Apr;22:49-61. doi: 10.1016/j.molmet.2019.01.013. Epub 2019 Feb 5.

24.

Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease.

Mantovani A, Zusi C, Sani E, Colecchia A, Lippi G, Zaza GL, Valenti L, Byrne CD, Maffeis C, Bonora E, Targher G.

Diabetes Metab. 2019 Oct;45(5):480-487. doi: 10.1016/j.diabet.2019.01.011. Epub 2019 Feb 11.

PMID:
30763699
25.

Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.

Santos RD, Valenti L, Romeo S.

Atherosclerosis. 2019 Mar;282:110-120. doi: 10.1016/j.atherosclerosis.2019.01.029. Epub 2019 Jan 30. Review.

PMID:
30731283
26.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
27.

Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update.

Valenti LVC, Baselli GA.

Curr Pharm Des. 2018;24(38):4566-4573. doi: 10.2174/1381612825666190119113836. Review.

PMID:
30659533
28.

NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?

Valenti L, Nobili V.

Hepatobiliary Surg Nutr. 2018 Dec;7(6):484-486. doi: 10.21037/hbsn.2018.10.03. No abstract available.

29.

FibroScan Detects Cardiovascular Damage in Patients With NAFLD.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2018 Dec 8. pii: S1542-3565(18)31254-0. doi: 10.1016/j.cgh.2018.11.011. [Epub ahead of print]

PMID:
30528844
30.

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.

Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB.

Sci Transl Med. 2018 Nov 21;10(468). pii: eaat0344. doi: 10.1126/scitranslmed.aat0344.

31.

A bioassay-based protocol for chemical neutralization of human faecal wastes treated by physico-chemical disinfection processes: A case study on benzalkonium chloride.

Sozzi E, Baloch M, Strasser J, Fisher MB, Leifels M, Camacho J, Mishal N, Elmes SF, Allen G, Gadai G, Valenti L, Sobsey MD.

Int J Hyg Environ Health. 2019 Mar;222(2):155-167. doi: 10.1016/j.ijheh.2018.07.002. Epub 2018 Nov 10.

PMID:
30424942
32.

Beyond fat accumulation, NAFLD genetics converges on lipid droplet biology.

Baselli G, Valenti L.

J Lipid Res. 2019 Jan;60(1):7-8. doi: 10.1194/jlr.C091116. Epub 2018 Nov 12. No abstract available.

33.

Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease.

Pelusi S, Valenti L.

Liver Int. 2019 Feb;39(2):250-256. doi: 10.1111/liv.13972. Epub 2018 Oct 17. Review.

PMID:
30248234
34.

FGF23 and Fetuin-A Interaction in the Liver and in the Circulation.

Mattinzoli D, Ikehata M, Tsugawa K, Alfieri CM, Dongiovanni P, Trombetta E, Valenti L, Puliti A, Lazzari L, Messa P.

Int J Biol Sci. 2018 Apr 25;14(6):586-598. doi: 10.7150/ijbs.23256. eCollection 2018.

35.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

36.

Effect of Sexual Intercourse on Lower Extremity Muscle Force in Strength-Trained Men.

Valenti LM, Suchil C, Beltran G, Rogers RC, Massey EA, Astorino TA.

J Sex Med. 2018 Jun;15(6):888-893. doi: 10.1016/j.jsxm.2018.04.636. Epub 2018 May 9.

PMID:
29753800
37.

Albumin biofunctionalization to minimize the Staphylococcus aureus adhesion on solid substrates.

Martín ML, Pfaffen V, Valenti LE, Giacomelli CE.

Colloids Surf B Biointerfaces. 2018 Jul 1;167:156-164. doi: 10.1016/j.colsurfb.2018.04.006. Epub 2018 Apr 3.

PMID:
29649785
38.

Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.

Mancini M, Summers P, Faita F, Brunetto MR, Callea F, De Nicola A, Di Lascio N, Farinati F, Gastaldelli A, Gridelli B, Mirabelli P, Neri E, Salvadori PA, Rebelos E, Tiribelli C, Valenti L, Salvatore M, Bonino F.

World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. Review.

39.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
40.

Nonalcoholic Fatty Liver Disease in Children.

Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V.

Semin Liver Dis. 2018 Feb;38(1):1-13. doi: 10.1055/s-0038-1627456. Epub 2018 Feb 22. Review.

PMID:
29471561
41.

Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases?

Donati B, Valenti L.

Ann Transl Med. 2017 Dec;5(23):472. doi: 10.21037/atm.2017.09.37. No abstract available.

42.

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.

43.

Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis.

Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, Biondetti P, Fargion S, Fracanzani AL.

Atherosclerosis. 2018 Jan;268:27-31. doi: 10.1016/j.atherosclerosis.2017.11.012. Epub 2017 Nov 16.

PMID:
29175651
44.

Genetics and epigenetics of NAFLD and NASH: Clinical impact.

Eslam M, Valenti L, Romeo S.

J Hepatol. 2018 Feb;68(2):268-279. doi: 10.1016/j.jhep.2017.09.003. Epub 2017 Nov 6. Review.

PMID:
29122391
45.

myVCF: a desktop application for high-throughput mutations data management.

Pietrelli A, Valenti L.

Bioinformatics. 2017 Nov 15;33(22):3676-3678. doi: 10.1093/bioinformatics/btx475.

PMID:
29036298
46.

Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease.

Pigoni A, Iuculano F, Saetti C, Airaghi L, Burdick L, Spreafico S, Curioni M, Lombardi R, Valenti L, Fracanzani AL, Fargion S.

Metab Brain Dis. 2018 Feb;33(1):347-352. doi: 10.1007/s11011-017-0107-0. Epub 2017 Sep 16.

PMID:
28918510
47.

Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Kim K, Ryu D, Dongiovanni P, Ozcan L, Nayak S, Ueberheide B, Valenti L, Auwerx J, Pajvani UB.

Gastroenterology. 2017 Dec;153(6):1568-1580.e10. doi: 10.1053/j.gastro.2017.08.039. Epub 2017 Aug 30.

48.

The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.

Liu Z, Que S, Zhou L, Zheng S, Romeo S, Mardinoglu A, Valenti L.

Sci Rep. 2017 Aug 24;7(1):9273. doi: 10.1038/s41598-017-09548-9.

49.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A.

Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.

PMID:
28741298
50.

A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease.

Dongiovanni P, Valenti L.

Int J Mol Sci. 2017 Jul 16;18(7). pii: E1534. doi: 10.3390/ijms18071534. Review.

Supplemental Content

Loading ...
Support Center